Oxycodegol phosphate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414434

CAS#: 1415126-69-0 (phosphate)

Description: Oxycodegol phosphate is a mu​-opioid agonist used in the treatment of Moderate to Severe Chronic Low Back Pain


Chemical Structure

img
Oxycodegol phosphate
CAS# 1415126-69-0 (phosphate)

Theoretical Analysis

MedKoo Cat#: 414434
Name: Oxycodegol phosphate
CAS#: 1415126-69-0 (phosphate)
Chemical Formula: C31H50NO13P
Exact Mass: 675.302
Molecular Weight: 675.71
Elemental Analysis: C, 55.10; H, 7.46; N, 2.07; O, 30.78; P, 4.58

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1415126-69-0 (phosphate); 1211231-85-4 (trifluoroacetate); 1211231-53-6 (HCl); 1211231-76-3 (free base)  

Synonym: Oxycodegol phosphate; NKTR181 phosphate; NKTR 181 phosphate; NKTR-181 phosphate

IUPAC/Chemical Name: Morphinan-14-ol, 4,5-epoxy-6-(3,6,9,12,15,18-hexaoxanonadec-1-yloxy)-3-methoxy-17-methyl-, (5alpha,6alpha)-, phosphate (1:1)

InChi Key: QRHDLOZMIJYWAN-YZMBXOLFSA-N

InChi Code: InChI=1S/C31H50NO13P/c1-32-9-8-30-27-23-4-5-24(37-3)28(27)44-29(30)25(6-7-31(30,26(32)22-23)45-46(33,34)35)43-21-20-42-19-18-41-17-16-40-15-14-39-13-12-38-11-10-36-2/h4-5,25-26,29H,6-22H2,1-3H3,(H2,33,34,35)/t25-,26-,29+,30+,31-/m1/s1

SMILES Code: CN(CC1)[C@H]2[C@]3(OP(O)(O)=O)CC[C@@H](OCCOCCOCCOCCOCCOCCOC)[C@@]4([H])[C@]31C5=C(O4)C(OC)=CC=C5C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 675.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Henningfield JE, Gudin J, Rauck R, Gimbel J, Tagliaferri M, Doberstein SK, Di Fonzo C, Lu L, Katz N, Siddhanti S, Schnoll S. Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain. Pain Med. 2020 Aug 1;21(8):1553-1561. doi: 10.1093/pm/pnz326. PMID: 32150255; PMCID: PMC7530570.

2: Ge X, Henningfield JE, Siddhanti S, Jobes J, Lu L, Xie S, Ziola M, Kelsh D, Vince B, Di Fonzo CJ, Tagliaferri M, Zalevsky J, Doberstein SK, Hoch U, Eldon MA. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study. Pain Med. 2020 Feb 1;21(2):e114-e126. doi: 10.1093/pm/pnz232. PMID: 31553457.

3: Gudin J, Rauck R, Argoff C, Agaiby E, Gimbel J, Katz N, Doberstein SK, Tagliaferri M, Tagliaferri M, Potts J, Wild J, Lu L, Siddhanti S, Hale M, Markman J. Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS). Pain Med. 2020 Nov 7;21(7):1347-1356. doi: 10.1093/pm/pnz169. PMID: 31361019; PMCID: PMC7372935.